SCHEMBL1049663

SCHEMBL1049663

COc1c(C(C)(C)C)ccc(O)c1O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 4/20 0.45
CA1 P00915 2/20 0.45
ALOX15 P16050 5/20 0.42
LMNA P02545 3/20 0.42
HPGD P15428 3/20 0.42
TP53 P04637 2/20 0.42
CYP3A4 P08684 2/20 0.42
ALDH1A1 P00352 8/20 0.42
HSD17B10 Q99714 3/20 0.42
TYR P14679 2/20 0.42
NR1I2 O75469 1/20 0.42
CYP2C9 P11712 1/20 0.42
MIF P14174 1/20 0.42
HTT P42858 1/20 0.42
NFE2L2 Q16236 1/20 0.42
TDP1 Q9NUW8 3/20 0.40
TSHR P16473 1/20 0.40
KDM4E B2RXH2 2/20 0.39
MAPT P10636 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22090225 0.82 CYP3A4 (0.46) CA2CA1ALOX15LMNAHPGD
SCHEMBL2552130 0.82 ALOX15 (0.41) CA2CA1ALOX15LMNAHPGD
SCHEMBL69650 0.79 PTGS1 (0.39) CA2CA1ALOX15LMNAHPGD
SCHEMBL1567262 0.78 ALOX15 (0.41) CA2CA1ALOX15LMNAHPGD
SCHEMBL11882012 0.77 MAPT (0.48) CA2CA1ALOX15LMNAHPGD
SCHEMBL29488075 0.75 ALDH1A1 (0.56) CA2CA1ALOX15LMNAHPGD
SCHEMBL7738982 0.75 PDE4A (0.38) CA2CA1ALOX15LMNAHPGD
SCHEMBL2686084 0.75 ALDH1A1 (0.56) CA2CA1ALOX15LMNAHPGD
SCHEMBL29488108 0.75 CA2 (0.56) CA2CA1ALOX15LMNAHPGD
SCHEMBL3169896 0.75 CA2 (0.56) CA2CA1ALOX15LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12016312-B2 Animal models, screening methods, and treatment methods for intraocular diseases or disorders Smilebiotek Zhuhai Limited (CN) 2024-06-25 US disclosed
US-12016312-B2 Animal models, screening methods, and treatment methods for intraocular diseases or disorders Smilebiotek Zhuhai Limited (CN) 2024-06-25 US disclosed
US-20220016146-A1 METHOD OF TREATING AGE-RELATED MACULAR DEGENERATION Smilebiotek Zhuhai Limited (CN) 2022-01-20 US disclosed
US-20220015338-A1 ANIMAL MODELS, SCREENING METHODS, AND TREATMENT METHODS FOR INTRAOCULAR DISEASES OR DISORDERS Smilebiotek Zhuhai Limited (CN) 2022-01-20 US disclosed
EP-2318477-B1 ADDITIVES TO PREVENT DEGRADATION OF CYCLIC ALKENE DERIVATIVES FUJIFILM ELECTRONIC MAT USA INC (US) 2019-06-05 EP disclosed
US-8252704-B2 Additives to prevent degradation of cyclic alkene derivatives FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. (US) 2012-08-28 US disclosed
US-20110259242-A1 Additives to Prevent Degradation of Cyclic Alkene Derivatives FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. (US) 2011-10-27 US disclosed
US-7985350-B2 Additives to prevent degradation of cyclic alkene derivatives FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. (US) 2011-07-26 US disclosed
EP-2318477-A1 ADDITIVES TO PREVENT DEGRADATION OF CYCLIC ALKENE DERIVATIVES FujiFilm Electronic Materials USA, Inc. (US) 2011-05-11 EP disclosed
US-20110091651-A1 Additives to Prevent Degradation of Cyclic Alkene Derivatives FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. (US) 2011-04-21 US disclosed
US-7871536-B2 Additives to prevent degradation of cyclic alkene derivatives FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. (US) 2011-01-18 US disclosed
WO-2010005937-A1 ADDITIVES TO PREVENT DEGRADATION OF CYCLIC ALKENE DERIVATIVES FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. (US) 2010-01-14 WO disclosed
US-20090291210-A1 Additives to Prevent Degradation of Cyclic Alkene Derivatives FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. (US) 2009-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220016146-A1 METHOD OF TREATING AGE-RELATED MACULAR DEGENERATION AGER, CASP3, PDE6D CA2 2631/4885CA1 4587/4885ALOX15 246/4885
US-12016312-B2 Animal models, screening methods, and treatment methods for intraocular diseases or disorders MB, MYOC, PDE6A CA2 2294/4885CA1 4560/4885ALOX15 567/4885
US-20220015338-A1 ANIMAL MODELS, SCREENING METHODS, AND TREATMENT METHODS FOR INTRAOCULAR DISEASES OR DISORDERS MB, MYOC, PDE6A CA2 2294/4885CA1 4560/4885ALOX15 567/4885
US-20110259242-A1 Additives to Prevent Degradation of Cyclic Alkene Derivatives GPX4, GPX1, NFE2L2 CA2 2525/4885CA1 2702/4885ALOX15 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.